Tradestie Institutional Equity Comparison Engine
CRMD vs REPL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while REPL counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRMD trades at 29.5x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus REPL at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRMD sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against REPL sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
CRMD 29.5x vs REPL N/M Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs +0.0%
Momentum & Technical Winner
REPL
1Y -58.2% vs +119.8% ยท 52W Pos 1% vs 83%
Options & Structure Winner
REPL
BREAKDOWN (22nd %ile IV) vs BREAKOUT (23rd %ile IV)
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap
$370.6M
1M Return
-36.38%
1Y Return
-58.23%
Forward P/E
29.5x
Unified AI Score
55.5 / 100
HOLD
Tech 60.0
Fund 62.0
Flow 70.0
Mom 55.0
REPL
NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$19.74
-7.8% 1D
Market Cap
$2.1B
1M Return
+78.64%
1Y Return
+119.82%
Forward P/E
N/M
Unified AI Score
34.8 / 100
SELL
Tech 16.0
Fund 44.0
Flow 70.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRMD -58.23%
REPL +119.82%
Spread: +177.81 pp (REPL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CRMD TTM Op. Margin: 41.0%
REPL TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs REPL. Trailing 12-month operating profitability (CRMD 41.0% vs REPL 0.0%) and valuation multiples (CRMD 29.5x vs REPL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | REPL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $370.6M | $2.1B | Larger Scale | REPL |
| Trailing P/E Ratio Valuation | 2.4x | N/M | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 29.5x | N/M | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -47.7% | +0.0% | Higher Growth | REPL |
| Operating Margin (TTM) Profitability | 41.0% | 0.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 15.5% | 0.0% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 15.3% | -115.8% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 1% ($5โ$13) | 83% ($2โ$24) | Stronger Trend | REPL |
| Beta / 30D Volatility Risk Regime | 1.22ฮฒ ยท 103% Vol | 2.14ฮฒ ยท 104% Vol | Lower Realized Risk | CRMD |
| Unified Institutional Score Composite Signal | 55.5 / 100 (HOLD) | 34.8 / 100 (SELL) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRMD vs REPL Buy Guide
CRMD
BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
REPL
BREAKOUT
99d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRMD nor REPL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.